Université de Genève has a strong international reputation, both for the quality of its research and the excellence of its education. The Faculty of Medicine is well‐known internationally and leads research in partnership with the largest hospital in Switzerland, the Geneva University Hospitals.
The group has ample experience in clinical and translational research in AD, including clinical trials. Scientific interests include neuroimaging and biomarkers in persons at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences and technology are translated to a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. UNIGE cooperates with the Italian National Centre for AD in Brescia, allowing access to personnel and know‐how on advanced brain image analysis.
Clinical neurologist, Full Professor of Clinical Neuroscience at the University of Geneva, Switzerland, and Head of the Memory Clinic of the Geneva University Hospital. Former Scientific Director at the National Alzheimer’s Centre in Brescia, Italy, leads a team of 25 imaging scientists in Italy and 10 scientists in Geneva. Author of over 500 scientific papers listed in PubMed, imaging editor for Neurobiology of Aging, and founding editorial board member of The Lancet Neurology. Has led national and international projects funded by the European Commission, the Alzheimer’s Association, Italian and Swiss Ministry of Health, and industry. Over the years, he has attracted over 25M euros in competitive research funds. Chairman of Alzheimer’s Imaging Consortium at International Conference on Alzheimer’s Disease in 2010-2011. Honorary member of the Austrian Neurological Society, has received the Lyons Career ward in 2013. Principal Investigator of EC funded projects that led to the development of the neuGRID infrastructure for imaging neuroscientists based on cloud computing. Has brought ADNI to Europe with Alzheimer’s Association grant Pilot European ADNI in 2005-6 and IMI Pharmacog WP5/EADNI in 2010. Has brought ADNI and DIAN to Italy with Italian Ministry of Health-funded Italian ADNI and Italian DIAN (2012- ongoing). Has led the international Alzheimer’s Association Harmonized Protocol for Manual Hippocampal Segmentation. Has brought amyloid PET to Italy thanks to investigator-initiated sponsored studies with florbetapir, flutemetamol, and florbetaben and tau PET to Switzerlandmthanks to H2020 coSTREAM. National lead for Switzerland and Italy of IMI EPAD – European Prevention of Alzheimer’s Disease, leads the diagnostic branch of IMI2 AMYPAD, the amyloid PET chapter of EPAD.
Margherita Mauri, MS (female) graduated in Economics and International Relations has been working in project management of European and international project since 2011.
Eleni Pilichou is psychiatrist-psychotherapist at the Geneva University Hospitals, at the section of Geriatric Psychiatry and of the Memory Clinic. She graduated from the Faculty of Medicine of Athens, Greece in 2009 she completed her specialization in psychiatry-psychotherapy in Geneva, Switzerland. She has an interest and an experience in geriatric psychopathology and cognition. Dr Pilichou is currently following a specialization in Psychogeriatrics in the Swiss Society of Psychiatry and Psychotherapy of the Elderly and a three-year advanced diploma course in Psychoanalytic Psychotherapy at the University of Geneva.
Marie-Louise Montadon, is a psychologis in neuroscience with particular interest in the area of aging and neurodegenerative diseases. She was actively involved in developing imaging solutions for neuroscience research and clinical diagnosis (particularly neurodegenerative disorders) in addition to lecturing undergraduate and postgraduate courses on medical imaging. Her academic accomplishments in the area of quantitative brain PET imaging have been well recognized since she is recipient of many awards and distinctions among which the 2005 best PhD thesis award given by the Medical School of Geneva University and the Research Grant for the Advancement of Women 2004 given by the Advisory Board for the Advancement of Women, National Center of Competence in Research CO-ME (Computer Aided and Image Guided Medical Interventions). Since 2013, Dr. M.-L. Montandon has been investigating elderly clinical populations with and without cognitive impairment. In this context, she has a particular interest in the identification of MRI and PET markers of cognitive decline in normal aging and in mild cognitive impairment. Moreover, she has been using neuropsychological, genetic and metabolic information for characterization of subgroups with increased risk for AD.